These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 19159568)

  • 1. [Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].
    Liu RB; Zhou XH; Wang JN; Liang HZ; Li XX; Wu ZH; Ye JL; Wang SM
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3397-400. PubMed ID: 19159568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors.
    Qi G; Zhang X; Gai X; Yan X
    PeerJ; 2024; 12():e17377. PubMed ID: 38766488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types.
    Budzik MP; Patera J; Sobol M; Czerw AI; Deptała A; Badowska-Kozakiewicz AM
    Breast; 2019 Feb; 43():135-141. PubMed ID: 30553188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated With Node-Positive Disease in Estrogen Receptor-Positive Breast Cancer Patients.
    Gallagher J; Elleson KM; Englander K; Chintapally N; Sun W; Whiting J; Laronga C; Lee MC
    J Surg Res; 2024 Mar; 295():327-331. PubMed ID: 38061237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
    Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
    Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of DNA methylation marker of paired-like homeodomain transcription factor 2 and growth receptors in invasive ductal carcinoma of the breast.
    Wan Abdul Rahman WF; Fauzi MH; Jaafar H
    Asian Pac J Cancer Prev; 2014; 15(19):8441-5. PubMed ID: 25339043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
    Khabaz MN
    Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
    Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.
    Liu J; Deng H; Jia W; Zeng Y; Rao N; Li S; Jin L; Wu J; Song E; Su F
    J Cancer Res Clin Oncol; 2012 May; 138(5):837-42. PubMed ID: 22290394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor conversion in distant breast cancer metastases.
    Hoefnagel LD; van de Vijver MJ; van Slooten HJ; Wesseling P; Wesseling J; Westenend PJ; Bart J; Seldenrijk CA; Nagtegaal ID; Oudejans J; van der Valk P; van der Groep P; de Vries EG; van der Wall E; van Diest PJ
    Breast Cancer Res; 2010; 12(5):R75. PubMed ID: 20863372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment.
    Wu H; Guan S; Sun M; Yu Z; Zhao L; He M; Zhao H; Yao W; Wang E; Jin F; Xiao Q; Wei M
    PLoS One; 2015; 10(5):e0126128. PubMed ID: 25961581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
    Badowska-Kozakiewicz A; Sobol M; Patera J
    Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.
    Ambroise M; Ghosh M; Mallikarjuna VS; Kurian A
    Asian Pac J Cancer Prev; 2011; 12(3):625-9. PubMed ID: 21627355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.